These risk scores aim to encapsulate the overall health of a patient based on the patient’s comorbidity history. previously proposed comorbidity measures to predict mortality using diagnoses of chronic diseases and health conditions. This does not alter our adherence to PLOS ONE policies on sharing data and materials.Ĭharlson et. No other potential conflicts of interest exist. BDH is the PI of grants funded by Intermountain Healthcare’s Foundry innovation program, the Intermountain Research and Medical Foundation, CareCentra, GlaxoSmithKline, and AstraZeneca for the development and/or clinical implementation of clinical decision tools. The funding source had no role in the design of the study, the data analysis, the interpretation of the findings, or the writing or publication of the study manuscript.Ĭompeting interests: BDH and JLA are inventors of IMRS and other clinical decision tools that are licensed to CareCentra and Alluceo. Horne, PhD, MStat, MPH ( or Patti Spencer ( Research Director, Cardiovascular and Neurosciences, Intermountain Healthcare).įunding: This study was funded by internal institutional sources. Data are available through collaborative contract with Intermountain Healthcare by contacting Benjamin D. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.ĭata Availability: Due to ethical restrictions related to protecting patient confidentiality arising from US Federal law (HIPAA) and the Intermountain Healthcare Institutional Review Board, data cannot be made publicly available. Received: SeptemAccepted: Published: May 21, 2020Ĭopyright: © 2020 Snow et al. Orueta, Osakidetza Basque Health Service, SPAIN (2020) Comparative evaluation of the clinical laboratory-based Intermountain risk score with the Charlson and Elixhauser comorbidity indices for mortality prediction. Citation: Snow GL, Bledsoe JR, Butler A, Wilson EL, Rea S, Majercik S, et al.
0 kommentar(er)
